News
8h
Zacks.com on MSNHere's What to Expect From Pfizer's Non-Oncology Drugs in Q2 EarningsPFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.
Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results